ESMO 23: MARIPOSA Data Blunt J&J’s Rybrevant Threat To Tagrisso

Decidedly mixed data from the MARIPOSA study released early from the ESMO meeting suggest that Johnson & Johnson’s Rybrevant poses less of a threat to AstraZeneca’s best-selling drug, Tagrisso, than had been mooted. More data on safety and overall survival should prove telling.